Directorate Change

About this update from Cambridge Cognition Holdings Plc

  18 October 2024 Cambridge Cognition Holdings plc ("Cambridge Cognition", the "Company" or the "Group")   Directorate change   Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that, further to the announcement made on 12 September 2024 in which it stated that Dr Matthew Stork had stepped down as Chief Executive Officer, the Company has now received the formal resignation of Dr Stork as a Director of the Company and all subsidiary entities of which he was a Director.      Enquiries:   Cambridge Cognition Holdings plc   Dr Steven Powell, Chairman c/o Hudson Sandler   Panmure Liberum Limited (NOMAD and Joint Broker)   Freddy Crossley / Will Goode / Mark Rogers   Rupert Dearden   Tel: 020 7886 2968   (Corporate Finance)   (Corporate Broking)     Dowgate Capital Limited (Joint Broker)   David Poutney / James Serjeant     Tel: 020 3903 7715       Hudson Sandler (Financial PR and IR)   Dan de Belder / Hattie Dreyfus  / Harry Griffiths   Tel: 020 7796 4133   [email protected]   Notes to Editors   About Cambridge Cognition   Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.   For further information visit: https://cambridgecognition.com/    

View stock analysis, news, and events for Cambridge Cognition Holdings Plc